{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:06:04Z","timestamp":1790805964004,"version":"4.1.0"},"reference-count":117,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T00:00:00Z","timestamp":1640131200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Although many endocrine diseases can be associated with acquired cardiomyopathy and heart failure, conditions except hypothyroidism, hyperthyroidism, phaeochromocytoma-paraganglioma (PPGL), and primary hyperaldosteronism are rare. PPGL is a rare catecholamine-secreting neuroendocrine tumour arising from the adrenal gland in 80\u201385% or extra-adrenal chromaffin cells of the autonomic neural ganglia in the remainder. The annual incidence of PPGL is 3\u20138 cases per million per year in the general population. Catecholamine-induced cardiomyopathy (CICMP) has got a prevalence of 8\u201311% among patients with PPGL. Hypertension, either sustained or episodic, is present in the vast majority (95%) of PPGL patients. However, among patients with CICMP, hypertension is present only in 65% of cases and the classical triad of paroxysmal headache, sweating, and palpitation is present only in 4%. Based on the cardiac remodelling in response to endogenous catecholamine excess, PPGL patients might present with one of the three CICMPs, including dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), or Takotsubo cardiomyopathy (TCM). Regardless of the subtypes, all CICMPs have many features in common \u2014 a dramatic clinical presentation, reversible cardiomyopathy, similar repolarisation electrocardiography changes, mild-moderate cardiac biomarker elevation, and normal coronary arteries on coronary angiography. CICMP should be suspected in patients with non-ischaemic, non-valvular forms of cardiomyopathy, even in those without definite features of catecholamine excess. PPGL associated TCM should be suspected in all acute coronary syndrome (ACS) patients exhibiting pronounced blood pressure variability with no culprit lesions on coronary angiography. This article will provide a review of the various CICMPs, their pathophysiology, clinical features, and the management options.<\/jats:p>","DOI":"10.31083\/j.rcm2204130","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T02:04:36Z","timestamp":1640225076000},"source":"Crossref","is-referenced-by-count":44,"title":["Catecholamine-induced cardiomyopathy: an endocrinologist\u2019s perspective"],"prefix":"10.31083","volume":"22","author":[{"given":"Aman","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Birmingham Medical School, B15 2TH Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M","family":"Pappachan","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, PR2 9HT Preston, UK"},{"name":"Faculty of Science, Manchester Metropolitan University, M15 6BH Manchester, UK"},{"name":"Faculty of Biology, Medicine and Health, The University of Manchester, M13 9PL Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius James","family":"Fernandez","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Pilgrim Hospital, PE21 9QS Boston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2021,12,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2008; 29: 270\u2013276.","DOI":"10.1093\/eurheartj\/ehm342"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Briceno N, Schuster A, Lumley M, Perera D. Ischaemic cardiomyopathy: pathophysiology, assessment and the role of revascularisation. Heart. 2016; 102: 397\u2013406.","DOI":"10.1136\/heartjnl-2015-308037"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Hinton RB, Ware SM. Heart Failure in Pediatric Patients with Congenital Heart Disease. Circulation Research. 2017; 120: 978\u2013994.","DOI":"10.1161\/CIRCRESAHA.116.308996"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Kuroda K. Hypertensive cardiomyopathy: a clinical approach and literature review. World Journal of Hypertension. 2015; 5: 41.","DOI":"10.5494\/wjh.v5.i2.41"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Rapezzi C, Arbustini E, Caforio ALP, Charron P, Gimeno-Blanes J, Helio T, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. a position statement from the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2013; 34: 1448\u20131458.","DOI":"10.1093\/eurheartj\/ehs397"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Arbustini E, Narula N, Tavazzi L, Serio A, Grasso M, Favalli V, et al. The MOGE(S) classification of cardiomyopathy for clinicians. Journal of the American College of Cardiology. 2014; 64: 304\u2013318.","DOI":"10.1016\/j.jacc.2014.05.027"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, et al. The MOGE(S) Classification for a Phenotype-Genotype Nomenclature of Cardiomyopathy: Endorsed by the World Heart Federation. Global Heart. 2013; 8: 355\u2013382.","DOI":"10.1016\/j.gheart.2013.11.001"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Khatiwada S, Boro H, Farooqui FA, Alam S. Endocrine causes of heart failure: a clinical primer for cardiologists. Indian Heart Journal. 2021; 73: 14\u201321.","DOI":"10.1016\/j.ihj.2020.11.003"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Agrawal S, Shirani J, Garg L, Singh A, Longo S, Longo A, et al. Pheochromocytoma and stress cardiomyopathy: Insight into pathogenesis. World Journal of Cardiology. 2017; 9: 255\u2013260.","DOI":"10.4330\/wjc.v9.i3.255"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Rastogi P, Dua A, Attri S, Sharma H. Hypothyroidism-induced reversible dilated cardiomyopathy. Journal of Postgraduate Medicine. 2018; 64: 177\u2013179.","DOI":"10.4103\/jpgm.JPGM_154_17"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Oliveros-Ruiz L, Vallejo M, Diez Canseco LF, C\u00e1rdenas M, Hermosillo JAG. Determinants of thyrotoxic cardiomyopathy recovery. BioMed Research International. 2013; 2013: 452709.","DOI":"10.1155\/2013\/452709"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Zhang J, Yang J, Li Y. Dilated cardiomyopathy and aldosteronoma: a causal link? ESC Heart Failure. 2020; 7: 331\u2013333.","DOI":"10.1002\/ehf2.12579"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Frustaci A, Letizia C, Verardo R, Grande C, Francone M, Sansone L, et al. Primary aldosteronism-associated cardiomyopathy: Clinical-pathologic impact of aldosterone normalization. International Journal of Cardiology. 2019; 292: 141\u2013147.","DOI":"10.1016\/j.ijcard.2019.06.055"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Pingle S, Shah T, Mosleh W, Kim AS. Cushing syndrome cardiomyopathy: an unusual manifestation of small\u2010cell lung cancer. ESC Heart Failure. 2020; 7: 3189\u20133192.","DOI":"10.1002\/ehf2.12860"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Yokota F, Arima H, Hirano M, Uchikawa T, Inden Y, Nagatani T, et al. Normalisation of plasma growth hormone levels improved cardiac dysfunction due to acromegalic cardiomyopathy with severe fibrosis. BMJ Case Reports. 2010; 2010: bcr1220092559.","DOI":"10.1136\/bcr.12.2009.2559"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Bansal B, Bansal M, Bajpai P, Garewal HK. Hypocalcemic cardiomyopathy-different mechanisms in adult and pediatric cases. The Journal of Clinical Endocrinology and Metabolism. 2014; 99: 2627\u20132632.","DOI":"10.1210\/jc.2013-3352"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Hunter L, Ferguson R, McDevitt H. Vitamin D deficiency cardiomyopathy in Scotland: a retrospective review of the last decade. Archives of Disease in Childhood. 2020; 105: 853\u2013856.","DOI":"10.1136\/archdischild-2019-317794"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and management. Heart. 2004; 90: 1224\u20131228.","DOI":"10.1136\/hrt.2004.040329"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Lupsa BC, Sachdev V, Lungu AO, Rosing DR, Gorden P. Cardiomyopathy in congenital and acquired generalized lipodystrophy: a clinical assessment. Medicine. 2010; 89: 245\u2013250.","DOI":"10.1097\/MD.0b013e3181e9442f"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Lenders JWM, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005; 366: 665\u2013675.","DOI":"10.1016\/S0140-6736(05)67139-5"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Santos JRU, Brofferio A, Viana B, Pacak K. Catecholamine-Induced Cardiomyopathy in Pheochromocytoma: how to Manage a Rare Complication in a Rare Disease? Hormone and Metabolic Research. 2019; 51: 458\u2013469.","DOI":"10.1055\/a-0669-9556"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Park J, Kim KS, Sul J, Shin SK, Kim JH, Lee J, et al. Prevalence and patterns of left ventricular dysfunction in patients with pheochromocytoma. Journal of Cardiovascular Ultrasound. 2011; 19: 76\u201382.","DOI":"10.4250\/jcu.2011.19.2.76"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Giavarini A, Chedid A, Bobrie G, Plouin P, Hag\u00e8ge A, Amar L. Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma. Heart. 2013; 99: 1438\u20131444.","DOI":"10.1136\/heartjnl-2013-304073"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine Metabolism: a Contemporary View with Implications for Physiology and Medicine. Pharmacological Reviews. 2004; 56: 331\u2013349.","DOI":"10.1124\/pr.56.3.1"},{"key":"ref25","unstructured":"Pocock G, Richards CD. Human physiology: the basis of medicine. 3rd edn. Oxford University Press: Oxford. 2006."},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Gubbi S, Nazari MA, Taieb D, Klubo-Gwiezdzinska J, Pacak K. Catecholamine physiology and its implications in patients with COVID-19. The Lancet Diabetes & Endocrinology. 2020; 8: 978\u2013986.","DOI":"10.1016\/S2213-8587(20)30342-9"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Gordan R, Gwathmey JK, Xie L. Autonomic and endocrine control of cardiovascular function. World Journal of Cardiology. 2015; 7: 204\u2013214.","DOI":"10.4330\/wjc.v7.i4.204"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Kassim TA, Clarke DD, Mai VQ, Clyde PW, Mohamed Shakir KM. Catecholamine-induced cardiomyopathy. Endocrine Practice. 2008; 14: 1137\u20131149.","DOI":"10.4158\/EP.14.9.1137"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Redfield MM, Kay GN, Jenkins LS, Mianulli M, Jensen DN, Ellenbogen KA. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clinic Proceedings. 2000; 75: 790\u2013795.","DOI":"10.4065\/75.8.790"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Jacob JL, da Silveira LC, de Freitas CG, C\u00eantola CA, Nicolau JC, Lorga AM. Pheochromocytoma with echocardiographic features of obstructive hypertrophic cardiomyopathy: a case report. Angiology. 1994; 45: 985\u2013989.","DOI":"10.1177\/000331979404501113"},{"key":"ref31","unstructured":"Fleckenstein A, Janke J, Doring HJ, Pachinger O. Ca overload as the determinant factor in the production of catecholamine induced myocardial lesion. Recent Advances in Studies on Cardiac Structure and Metabolism. 1973; 2: 455\u2013266."},{"key":"ref32","unstructured":"Rona G, Kahn DS, Chappel CI. Studies on infarct-like myocardial necrosis produced by isoproterenol: a review. Revue Canadienne De Biologie. 1996; 22: 241\u2013255."},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Nakano T, Onoue K, Nakada Y, Nakagawa H, Kumazawa T, Ueda T, et al. Alteration of \u03b2-adrenoceptor signalling in left ventricle of acute phase Takotsubo syndrome: a human study. Scientific Reports. 2018; 8: 12731.","DOI":"10.1038\/s41598-018-31034-z"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Paur H, Wright PT, Sikkel MB, Tranter MH, Mansfield C, O\u2019Gara P, et al. High levels of circulating epinephrine trigger apical cardiodepression in a \u03b22-adrenergic receptor\/Gi-dependent manner: a new model of Takotsubo cardiomyopathy. Circulation. 2012; 126: 697\u2013706.","DOI":"10.1161\/CIRCULATIONAHA.112.111591"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Heubach JF, Ravens U, Kaumann AJ. Epinephrine activates both Gs and Gi pathways, but norepinephrine activates only the Gs pathway through human beta2-adrenoceptors overexpressed in mouse heart. Molecular Pharmacology. 2004; 65: 1313\u20131322.","DOI":"10.1124\/mol.65.5.1313"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Ziele\u0144 P, Klisiewicz A, Januszewicz A, Prejbisz A, Kabat M, Peczkowska M, et al. Pheochromocytoma-related \u2018classic\u2019 takotsubo cardiomyopathy. Journal of Human Hypertension. 2010; 24: 363\u2013366.","DOI":"10.1038\/jhh.2009.115"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Chesley A, Lundberg MS, Asai T, Xiao RP, Ohtani S, Lakatta EG, et al. The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3\u2019-kinase. Circulation Research. 2000; 87: 1172\u20131179.","DOI":"10.1161\/01.RES.87.12.1172"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Santulli G, Campanile A, Spinelli L, Assante di Panzillo E, Ciccarelli M, Trimarco B, et al. G protein-coupled receptor kinase 2 in patients with acute myocardial infarction. The American Journal of Cardiology. 2011; 107: 1125\u20131130.","DOI":"10.1016\/j.amjcard.2010.12.006"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Batisse-Lignier M, Pereira B, Motreff P, Pierrard R, Burnot C, Vorilhon C, et al. Acute and Chronic Pheochromocytoma-Induced Cardiomyopathies: Different Prognoses?: a Systematic Analytical Review. Medicine. 2015; 94: e2198.","DOI":"10.1097\/MD.0000000000002198"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and risk of congestive heart failure. The New England Journal of Medicine. 2002; 347: 1135\u20131142.","DOI":"10.1056\/NEJMoa020803"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Dhalla NS. Formation of Aminochrome Leads to Cardiac Dysfunction and Sudden Cardiac Death. Circulation Research. 2018; 123: 409\u2013411.","DOI":"10.1161\/CIRCRESAHA.118.313416"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Adameova A, Abdellatif Y, Dhalla NS. Role of the excessive amounts of circulating catecholamines and glucocorticoids in stress-induced heart disease. Canadian Journal of Physiology and Pharmacology. 2009; 87: 493\u2013514.","DOI":"10.1139\/Y09-042"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Dhalla NS, Adameova A, Kaur M. Role of catecholamine oxidation in sudden cardiac death. Fundamental & Clinical Pharmacology. 2010; 24: 539\u2013546.","DOI":"10.1111\/j.1472-8206.2010.00836.x"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Whitelaw BC, Prague JK, Mustafa OG, Schulte KM, Hopkins PA, Gilbert JA, et al. Phaeochromocytoma crisis. Clinical Endocrinology. 2014; 80: 13\u201322.","DOI":"10.1111\/cen.12324"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Kimura S, Mitsuma W, Ito M, Suzuki H, Hosaka Y, Hirayama S, et al. Inverted Takotsubo contractile pattern caused by pheochromocytoma with tall upright T-waves, but not typical deep T-wave inversion. International Journal of Cardiology. 2010; 139: e15\u2013e17.","DOI":"10.1016\/j.ijcard.2008.06.073"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Lyon AR, Rees PSC, Prasad S, Poole-Wilson PA, Harding SE. Stress (Takotsubo) cardiomyopathy\u2013a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nature Clinical Practice. Cardiovascular Medicine. 2008; 5: 22\u201329.","DOI":"10.1038\/ncpcardio1066"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Y\u2010Hassan S, Falhammar H. Clinical features, complications, and outcomes of exogenous and endogenous catecholamine\u2010triggered Takotsubo syndrome: a systematic review and meta\u2010analysis of 156 published cases. Clinical Cardiology. 2020; 43: 459\u2013467.","DOI":"10.1002\/clc.23352"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circulation Research. 2013; 113: 739\u2013753.","DOI":"10.1161\/CIRCRESAHA.113.300308"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Ramchandra R, Hood SG, Xing D, Lambert GW, May CN. Mechanisms underlying the increased cardiac norepinephrine spillover in heart failure. American Journal of Physiology-Heart and Circulatory Physiology. 2018; 315: H340\u2013H347.","DOI":"10.1152\/ajpheart.00069.2018"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Kume T, Akasaka T, Kawamoto T, Yoshitani H, Watanabe N, Neishi Y, et al. Assessment of Coronary Microcirculation in Patients with Takotsubo-Like Left Ventricular Dysfunction. Circulation Journal. 2005; 69: 934\u2013939.","DOI":"10.1253\/circj.69.934"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Goldstein DS, Eisenhofer G, Kopin IJ. Sources and Significance of Plasma Levels of Catechols and their Metabolites in Humans. Journal of Pharmacology and Experimental Therapeutics. 2003; 305: 800\u2013811.","DOI":"10.1124\/jpet.103.049270"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Wittstein IS, Thiemann DR, Lima JAC, Baughman KL, Schulman SP, Gerstenblith G, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. The New England Journal of Medicine. 2005; 352: 539\u2013548.","DOI":"10.1056\/NEJMoa043046"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Merli E, Sutcliffe S, Gori M, Sutherland GGR. Tako-Tsubo cardiomyopathy: new insights into the possible underlying pathophysiology. European Journal of Echocardiography. 2006; 7: 53\u201361.","DOI":"10.1016\/j.euje.2005.08.003"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Coupez E, Eschalier R, Pereira B, Pierrard R, Souteyrand G, Clerfond G, et al. A single pathophysiological pathway in Takotsubo cardiomyopathy: Catecholaminergic stress. Archives of Cardiovascular Diseases. 2014; 107: 245\u2013252.","DOI":"10.1016\/j.acvd.2014.04.001"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Sharkey SW, Lesser JR, Zenovich AG, Maron MS, Lindberg J, Longe TF, et al. Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation. 2005; 111: 472\u2013479.","DOI":"10.1161\/01.CIR.0000153801.51470.EB"},{"key":"ref56","unstructured":"Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clinic Proceedings. 1983; 58: 802\u2013804."},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Satendra M, de Jesus C, Bordalo e S\u00e1 AL, Ros\u00e1rio L, Rocha J, Bicha Castelo H, et al. Reversible catecholamine-induced cardiomyopathy due to pheochromocytoma: Case report. Revista Portuguesa De Cardiologia. 2014; 33: 177.e1\u2013177.e6.","DOI":"10.1016\/j.repce.2013.09.014"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Al\u00ec A, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. The Journal of Clinical Endocrinology and Metabolism. 2000; 85: 637\u2013644.","DOI":"10.1210\/jc.85.2.637"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Ho AD, Feurle G, Gless KH, Brandeis WE. Normotensive familial phaeochromocytoma with predominant noradrenaline secretion. British Medical Journal. 1978; 1: 81\u201382.","DOI":"10.1136\/bmj.1.6105.81-a"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Pappachan JM, Tun NN, Arunagirinathan G, Sodi R, Hanna FWF. Pheochromocytomas and Hypertension. Current Hypertension Reports. 2018; 20: 3.","DOI":"10.1007\/s11906-018-0804-z"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Soltani A, Pourian M, Davani BM. Does this patient have Pheochromocytoma? A systematic review of clinical signs and symptoms. Journal of Diabetes & Metabolic Disorders. 2016; 15: 6.","DOI":"10.1186\/s40200-016-0226-x"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Hamidi O, Young WF, I\u00f1iguez-Ariza NM, Kittah NE, Gruber L, Bancos C, et al. Malignant Pheochromocytoma and Paraganglioma: 272 Patients over 55 Years. The Journal of Clinical Endocrinology and Metabolism. 2017; 102: 3296\u20133305.","DOI":"10.1210\/jc.2017-00992"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Malindretos PM, Sarafidis PA, Geropoulou EZ, Kapoulas S, Paramythiotis DD, Lasaridis AN. Sustained Hypotension Complicating an Extra-adrenal Pheochromocytoma. American Journal of Hypertension. 2008; 21: 840\u2013842.","DOI":"10.1038\/ajh.2008.179"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Kometani M, Yoneda T, Maeda Y, Oe M, Takeda Y, Higashitani T, et al. Pheochromocytoma crisis with cyclic fluctuation in blood pressure mimics acute coronary syndrome. Endocrinology, Diabetes & Metabolism Case Reports. 2020; 2020: 20-0115.","DOI":"10.1530\/EDM-20-0115"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Ionescu CN, Sakharova OV, Harwood MD, Caracciolo EA, Schoenfeld MH, Donohue TJ. Cyclic rapid fluctuation of hypertension and hypotension in pheochromocytoma. Journal of Clinical Hypertension. 2008; 10: 936\u2013940.","DOI":"10.1111\/j.1751-7176.2008.00046.x"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Kobal SL, Paran E, Jamali A, Mizrahi S, Siegel RJ, Leor J. Pheochromocytoma: cyclic attacks of hypertension alternating with hypotension. Nature Clinical Practice Cardiovascular Medicine. 2008; 5: 53\u201357.","DOI":"10.1038\/ncpcardio1054"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Ohara N, Uemura Y, Mezaki N, Kimura K, Kaneko M, Kuwano H, et al. Histopathological analysis of spontaneous large necrosis of adrenal pheochromocytoma manifested as acute attacks of alternating hypertension and hypotension: a case report. Journal of Medical Case Reports. 2016; 10: 279.","DOI":"10.1186\/s13256-016-1068-3"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Kaneto H, Kamei S, Tatsumi F, Shimoda M, Kimura T, Nakanishi S, et al. Case report: malignant pheochromocytoma without hypertension accompanied by increment of serum VEGF level and catecholamine cardiomyopathy. Frontiers in Endocrinology. 2021; 12: 688536.","DOI":"10.3389\/fendo.2021.688536"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Y-Hassan S, Falhammar H. Cardiovascular manifestations, and complications of pheochromocytomas and paragangliomas. Journal of Clinical Medicine. 2020; 9: 2435.","DOI":"10.3390\/jcm9082435"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Sedaia E, Esanu A, Ivanov V, Dumanschi C, Moiseeva A, Abra\u0219 M, et al. Catecholamine-induced cardiomyopathy in a patient with pheochromocytoma and polycystic kidney and liver disease: a case report. European Heart Journal-Case Reports. 2019; 3: ytz062.","DOI":"10.1093\/ehjcr\/ytz062"},{"key":"ref71","unstructured":"Quigg RJ, Om A. Reversal of severe cardiac systolic dysfunction caused by pheochromocytoma in a heart transplant candidate. The Journal of Heart and Lung Transplantation. 1994; 13: 525\u2013532."},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"McEntee RK, Coyle D, Meyer M. Severe dilated cardiomyopathy after propranolol treatment in an undiagnosed adrenal pheochromocytoma. Circulation: Heart Failure. 2011; 4: e10\u2013e12.","DOI":"10.1161\/CIRCHEARTFAILURE.111.961508"},{"key":"ref73","unstructured":"Gatzoulis KA, Tolis G, Theopistou A, Gialafos JH, Toutouzas PK. Cardiomyopathy due to a pheochromocytoma. A reversible entity. Acta Cardiologica. 1998; 53: 227\u2013229."},{"key":"ref74","unstructured":"Wilkenfeld C, Cohen M, Lansman SL, Courtney M, Dische MR, Pertsemlidis D, et al. Heart transplantation for end-stage cardiomyopathy caused by an occult pheochromocytoma. The Journal of Heart and Lung Transplantation. 1992; 11: 363\u2013366."},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Wani A, Adil A, Gardezi SAA, Jain R, Galazka P, Waples MJ, et al. Pheochromocytoma Presenting as Hypertrophic Obstructive Cardiomyopathy. JAMA Cardiology. 2021; 6: 974.","DOI":"10.1001\/jamacardio.2021.0944"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Schuiki ER, Jenni R, Amann FW, Ziegler WH. A reversible form of apical left ventricular hypertrophy associated with pheochromocytoma. Journal of the American Society of Echocardiography. 1993; 6: 327\u2013331.","DOI":"10.1016\/S0894-7317(14)80072-2"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Ghadri J, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. European Heart Journal. 2018; 39: 2032\u20132046.","DOI":"10.1093\/eurheartj\/ehy076"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Y-Hassan S. Clinical Features and Outcome of Pheochromocytoma-Induced Takotsubo Syndrome: Analysis of 80 Published Cases. The American Journal of Cardiology. 2016; 117: 1836\u20131844.","DOI":"10.1016\/j.amjcard.2016.03.019"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Agarwal V, Kant G, Hans N, Messerli FH. Takotsubo-like cardiomyopathy in pheochromocytoma. International Journal of Cardiology. 2011; 153: 241\u2013248.","DOI":"10.1016\/j.ijcard.2011.03.027"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Newell KA, Prinz RA, Pickleman J, Braithwaite S, Brooks M, Karson TH, et al. Pheochromocytoma multisystem crisis. A surgical emergency. Archives of Surgery. 1988; 123: 956\u2013959.","DOI":"10.1001\/archsurg.1988.01400320042007"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Davlouros PA, Velissaris D, Tsiola A, Filos KS, Alexopoulos D. Fever with multiple organ failure: not always sepsis. Anaesthesia and Intensive Care. 2010; 38: 1090\u20131093.","DOI":"10.1177\/0310057X1003800621"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Kang JM, Lee WJ, Kim WB, Kim TY, Koh JM, Hong SJ, et al. Systemic inflammatory syndrome and hepatic inflammatory cell infiltration caused by an interleukin-6 producing pheochromocytoma. Endocrine Journal. 2005; 52: 193\u2013198.","DOI":"10.1507\/endocrj.52.193"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Minetto M, Dovio A, Ventura M, Cappia S, Daffara F, Terzolo M, et al. Interleukin-6 producing pheochromocytoma presenting with acute inflammatory syndrome. Journal of Endocrinological Investigation. 2003; 26: 453\u2013457.","DOI":"10.1007\/BF03345202"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Lee T, Lin K, Chang C, Lew W, Lee T. Pheochromocytoma mimicking both acute coronary syndrome and sepsis: a case report. Medical Principles and Practice. 2013; 22: 405\u2013407.","DOI":"10.1159\/000343578"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Riester A, Weismann D, Quinkler M, Lichtenauer UD, Sommerey S, Halbritter R, et al. Life-threatening events in patients with pheochromocytoma. European Journal of Endocrinology. 2015; 173: 757\u2013764.","DOI":"10.1530\/EJE-15-0483"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Zhang R, Gupta D, Albert SG. Pheochromocytoma as a reversible cause of cardiomyopathy: Analysis and review of the literature. International Journal of Cardiology. 2017; 249: 319\u2013323.","DOI":"10.1016\/j.ijcard.2017.07.014"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Lenders JWM, Duh Q, Eisenhofer G, Gimenez-Roqueplo A, Grebe SKG, Murad MH, et al. Pheochromocytoma and Paraganglioma: an Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2014; 99: 1915\u20131942.","DOI":"10.1210\/jc.2014-1498"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"van Berkel A, Lenders JWM, Timmers HJLM. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma. European Journal of Endocrinology. 2014; 170: R109\u2013R119.","DOI":"10.1530\/EJE-13-0882"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JWM, et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. European Journal of Endocrinology. 2016; 174: G1\u2013G10.","DOI":"10.1530\/EJE-16-0033"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Rao D, Peitzsch M, Prejbisz A, Hanus K, Fassnacht M, Beuschlein F, et al. Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. European Journal of Endocrinology. 2017; 177: 103\u2013113.","DOI":"10.1530\/EJE-17-0077"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Mamoojee Y, Arham M, Elsaify W, Nag S. Lesson of the month 2: Catecholamine-induced cardiomyopathy - pitfalls in diagnosis and medical management. Clinical Medicine. 2016; 16: 201\u2013203.","DOI":"10.7861\/clinmedicine.16-2-201"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Bravo EL. Pheochromocytoma: new concepts and future trends. Kidney International. 1991; 40: 544\u2013556.","DOI":"10.1038\/ki.1991.244"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Timmers HJLM, Gimenez-Roqueplo A, Mannelli M, Pacak K. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocrine-Related Cancer. 2009; 16: 391\u2013400.","DOI":"10.1677\/ERC-08-0284"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Alsidawi S. Regional wall motion abnormalities in patients with pheochromocytoma. Hypertension Research. 2012; 35: 1135.","DOI":"10.1038\/hr.2012.149"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Agarwal V. Takotsubo Cardiomyopathy with Pheochromocytoma. JACC: Case Reports. 2019; 1: 91\u201393.","DOI":"10.1016\/j.jaccas.2019.07.004"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Ferreira VM, Marcelino M, Piechnik SK, Marini C, Karamitsos TD, Ntusi NAB, et al. Pheochromocytoma is Characterized by Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction. Journal of the American College of Cardiology. 2016; 67: 2364\u20132374.","DOI":"10.1016\/j.jacc.2016.03.543"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Madhavan M, Prasad A. Proposed Mayo Clinic criteria for the diagnosis of Tako-Tsubo cardiomyopathy and long-term prognosis. Herz. 2010; 35: 240\u2013243.","DOI":"10.1007\/s00059-010-3339-x"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Ghadri J, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. European Heart Journal. 2018; 39: 2047\u20132062.","DOI":"10.1093\/eurheartj\/ehy077"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Casey RT, Challis BG, Pitfield D, Mahroof RM, Jamieson N, Bhagra CJ, et al. Management of an acute catecholamine-induced cardiomyopathy and circulatory collapse: a multidisciplinary approach. Endocrinology, Diabetes & Metabolism Case Reports. 2017; 2017: 17-0122.","DOI":"10.1530\/EDM-17-0122"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Eisenhofer G, Rivers G, Rosas AL, Quezado Z, Manger WM, Pacak K. Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. Drug Safety. 2007; 30: 1031\u20131062.","DOI":"10.2165\/00002018-200730110-00004"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Takagi S, Miyazaki S, Fujii T, Daikoku S, Sutani Y, Morii I, et al. Dexamethasone-induced cardiogenic shock rescued by percutaneous cardiopulmonary support (PCPS) in a patient with pheochromocytoma. Japanese Circulation Journal. 2000; 64: 785\u2013788.","DOI":"10.1253\/jcj.64.785"},{"key":"ref102","unstructured":"Hoffman BB. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In Hardman JG, Limbird LE (eds.) Goodman & Gillman\u2019s: the pharmacological basis of therapeutics (pp. 215\u2013268). McGraw-Hill: Philadelphia. 2001."},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Prys-Roberts C, Farndon JR. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World Journal of Surgery. 2002; 26: 1037\u20131042.","DOI":"10.1007\/s00268-002-6667-z"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Min D. Catastrophic catecholamine-induced cardiomyopathy rescued by extracorporeal membrane oxygenation in recurrent malignant pheochromocytoma. Yeungnam University Journal of Medicine. 2019; 36: 254\u2013259.","DOI":"10.12701\/yujm.2019.00213"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Bouabdallaoui N, Bouchard D, Jolicoeur EM, Chronopoulos A, Garneau PY, Lamarche Y. Extracorporeal membrane oxygenation in pheochromocytoma-induced cardiogenic shock. Asian Cardiovascular & Thoracic Annals. 2018; 26: 314\u2013316.","DOI":"10.1177\/0218492317727995"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Matteucci M, Kowalewski M, Fina D, Jiritano F, Meani P, Raffa GM, et al. Extracorporeal life support for phaeochromocytoma-induced cardiogenic shock: a systematic review. Perfusion. 2020; 35: 20\u201328.","DOI":"10.1177\/0267659120908413"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Patel SM, Lipinski J, Al-Kindi SG, Patel T, Saric P, Li J, et al. Simultaneous Venoarterial Extracorporeal Membrane Oxygenation and Percutaneous Left Ventricular Decompression Therapy with Impella is Associated with Improved Outcomes in Refractory Cardiogenic Shock. ASAIO Journal. 2019; 65: 21\u201328.","DOI":"10.1097\/MAT.0000000000000767"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Shawa H, Bajaj M, Cunningham GR. Pheochromocytoma-Induced Atrial Tachycardia Leading to Cardiogenic Shock and Cardiac Arrest: Resolution with Atrioventricular Node Ablation and Pacemaker Placement. Texas Heart Institute Journal. 2014; 41: 660\u2013663.","DOI":"10.14503\/THIJ-13-3692"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"Salathe M, Weiss P, Ritz R. Rapid reversal of heart failure in a patient with phaeochromocytoma and catecholamine-induced cardiomyopathy who was treated with captopril. British Heart Journal. 1992; 68: 527\u2013528.","DOI":"10.1136\/hrt.68.11.527"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"Singal PK, Kapur N, Dhillon KS, Beamish RE, Dhalla NS. Role of free radicals in catecholamine induced cardiomyopathy. Canadian Journal of Physiology and Pharmacology. 1982; 60: 1390\u20131397.","DOI":"10.1139\/y82-207"},{"key":"ref111","doi-asserted-by":"crossref","unstructured":"Przyklenk K, Kloner RA. Relationship between structure and effects of ACE inhibitors: comparative effects in myocardial ischaemic\/reperfusion injury. British Journal of Clinical Pharmacology. 1989; 28: 167\u2013175.","DOI":"10.1111\/j.1365-2125.1989.tb03592.x"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Prejbisz A, Lenders JWM, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of phaeochromocytoma. Journal of Hypertension. 2011; 29: 2049\u20132060.","DOI":"10.1097\/HJH.0b013e32834a4ce9"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"Jia X, Guo X, Zheng Q. Perioperative management of paraganglioma and catecholamine-induced cardiomyopathy in child- a case report and review of the literature. BMC Anesthesiology. 2017; 17: 142.","DOI":"10.1186\/s12871-017-0433-0"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"Ramachandran R, Rewari V. Factors affecting the haemodynamic behaviour of patients undergoing pheochromocytoma and paraganglioma removal: a review. Cardiovascular Endocrinology. 2017; 6: 73\u201380.","DOI":"10.1097\/XCE.0000000000000090"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"Bonnefont-Rousselot D, Mahmoudi A, Mougenot N, Varoquaux O, Le Nahour G, Fouret P, et al. Catecholamine effects on cardiac remodelling, oxidative stress and fibrosis in experimental heart failure. Redox Report. 2002; 7: 145\u2013151.","DOI":"10.1179\/135100002125000389"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"Katsuumi G, Shimizu I, Yoshida Y, Hayashi Y, Ikegami R, Suda M, et al. Catecholamine-Induced Senescence of Endothelial Cells and Bone Marrow Cells Promotes Cardiac Dysfunction in Mice. International Heart Journal. 2018; 59: 837\u2013844.","DOI":"10.1536\/ihj.17-313"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"Shao Y, Redfors B, Stahlman M, Tang MS, Miljanovic A, Mollmann H, et al. A mouse model reveals an important role for catecholamine-induced lipotoxicity in the pathogenesis of stress-induced cardiomyopathy. European Journal of Heart Failure. 2013; 15: 9\u201322.","DOI":"10.1093\/eurjhf\/hfs161"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/4\/10.31083\/j.rcm2204130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T17:46:18Z","timestamp":1732729578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/4\/10.31083\/j.rcm2204130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,22]]},"references-count":117,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"alternative-id":["S1530-6550(21)00267-2"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2204130","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,22]]},"article-number":"1215"}}